Initiation and Maintenance of Low‐Dose Transdermal Testosterone in Non‐Binary Individuals: A Retrospective Audit
Most non-binary individuals initiating low-dose transdermal testosterone continue doses lower than those recommended in current guidelines after 6-12 months of treatment. These hypothesis-generating findings highlight the need for studies evaluating the influence of low-dose testosterone on clinical outcomes and safety end-points.
Authors
- Peter Locke
- Brendan J. Nolan (ORCID: https://orcid.org/0000-0001-8836-165X)
- Sav Zwickl
- Eli Ward‐Smith
- Ada S. Cheung
Institutions
- Abbotsford Veterinary Clinic (CA)
- Melbourne Health (AU)
- Austin Health (AU)
Publication Details
- Journal
- Clinical Endocrinology
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1111/cen.70110
- Primary Topic
- Hormonal and reproductive studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government
- Endocrine Society of Australia
- University of Melbourne
- Medical Research Council
- National Health and Medical Research Council